Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSPC Pharmaceutical GroupCSPCY -2.16%70 EV-to-EBITDA is 14.26 as of Aug. 02, 2026, which is 5% above its 10-year median of 13.54. GuruFocus rates CSPCY with a GF Score™ of 70/100 and a GF Value™ of $3.35 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 746 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks worse than 55.36% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CSPC Pharmaceutical Group's enterprise value is $11,310 Mil.
CSPC Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $793 Mil. Therefore, CSPC Pharmaceutical Group's EV-to-EBITDA for today is 14.26.
The historical rank and industry rank for CSPC Pharmaceutical Group's EV-to-EBITDA or its related term are showing as below:
CSPCY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.76 Med: 13.54 Max: 35.42
Current: 14.51
During the past 13 years, the highest EV-to-EBITDA of CSPC Pharmaceutical Group was 35.42. The lowest was 4.76. And the median was 13.54.
CSPCY's EV-to-EBITDA is ranked worse than 55.36% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs CSPCY: 14.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CSPC Pharmaceutical Group (OTCPK:CSPCY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CSPC Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
CSPC Pharmaceutical Group's share price for today is $4.305.
CSPC Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.162.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's EV-to-EBITDA falls into.
CSPC Pharmaceutical Group's current Enterprise Value is $11,310 Mil.
CSPC Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $793 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (CSPCY) has a EV-to-EBITDA of 14.26 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CSPC Pharmaceutical Group. This is near median its historical median of 13.54. Over the past decade, CSPC Pharmaceutical Group's EV-to-EBITDA has ranged from 4.76 to 35.42. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #413 out of 746 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is CSPC Pharmaceutical Group's EV-to-EBITDA too high?
CSPC Pharmaceutical Group's current EV-to-EBITDA of 14.26 is near median its 10-year median of 13.54. Over the past 10 years, this metric has ranged from a low of 4.76 to a high of 35.42. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. CSPC Pharmaceutical Group's value of 14.26 is 9.7% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #413 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #413 out of 746 companies for EV-to-EBITDA. This places CSPC Pharmaceutical Group in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. CSPC Pharmaceutical Group's value of 14.26 is 9.7% above this benchmark. Historically, CSPC Pharmaceutical Group's own EV-to-EBITDA has ranged from 4.76 to 35.42 over the past decade. While the company's 10-year median is 13.54 vs. the industry median of 13.00, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current EV-to-EBITDA of 14.26 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CSPC Pharmaceutical Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current EV-to-EBITDA is 14.26, which is near median its own 10-year median of 13.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.35, compared to a current price of $4.31 — trading 28.5% above its estimated fair value. The current EV-to-EBITDA is 14.26, which is near median its 10-year median of 13.54 and 9.7% above the Drug Manufacturers industry median of 13.00. CSPC Pharmaceutical Group's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current EV-to-EBITDA is 14.26 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $4.31 is trading 28.5% above its estimated GF Value™ of $3.35.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
EV-to-EBITDA: 14.26 (near median its 10-year median of 13.54)
GF Value™: $3.35 vs. price of $4.31 (28.5% above fair value)
Industry Position: 9.7% above the Drug Manufacturers median (#413 of 746)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
70GF Score
Get the complete analysis for CSPCY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
